CF · QJE Revise & Resubmit · Task 1
The three outcomes in the paper's original column order — (1) breakthrough, (2) gene share, (3) delay — rebuilt on TIGA value labels, under the paper's controls and with each GWAS-coverage control added. One table per specification.
Table 1. Outcomes on the value tier — paper controls only
| Value definition | (1) Post2000_TIGA_H | (2) share_gene_after | (3) Delay_To_TIGA_H | N | |||
|---|---|---|---|---|---|---|---|
| Medium | High | Medium | High | Medium | High | ||
| n_study | +0.299*** (0.044) | +0.763*** (0.037) |
−0.232*** (0.048) | −0.247*** (0.034) |
−3.932*** (0.617) | −26.974*** (0.630) |
5,515 |
| p-value (median) | +0.397*** (0.058) | +0.677*** (0.032) |
−0.211*** (0.060) | −0.253*** (0.034) |
−4.747*** (0.755) | −26.266*** (0.593) |
5,515 |
| p-value (max) | +0.354*** (0.065) | +0.698*** (0.033) |
−0.210*** (0.052) | −0.257*** (0.036) |
−4.197*** (0.796) | −26.564*** (0.632) |
5,515 |
| meanRankScore | +0.325*** (0.052) | +0.706*** (0.039) |
−0.232*** (0.056) | −0.244*** (0.034) |
−4.200*** (0.660) | −26.701*** (0.706) |
5,515 |
| odds ratio (median) | +0.652*** (0.099) | +0.700*** (0.034) |
−0.325*** (0.059) | −0.232*** (0.040) |
−6.543*** (1.117) | −25.494*** (0.562) |
5,515 |
| geneNtrait (gene-level) | +0.263*** (0.026) | +0.515*** (0.023) |
−0.058*** (0.022) | −0.075** (0.032) |
−3.621*** (0.369) | −22.980*** (0.333) |
5,515 |
| Disease-class FE · total publications · clustered SE | Yes | ||||||
| # TIGA-matched traits | No | ||||||
| # GWAS-hit opportunities | No | ||||||
Table 2. Outcomes on the value tier — paper controls + # TIGA-matched traits
| Value definition | (1) Post2000_TIGA_H | (2) share_gene_after | (3) Delay_To_TIGA_H | N | |||
|---|---|---|---|---|---|---|---|
| Medium | High | Medium | High | Medium | High | ||
| n_study | +0.191*** (0.045) | +0.634*** (0.040) |
−0.262*** (0.055) | −0.282*** (0.047) |
−2.850*** (0.647) | −25.692*** (0.667) |
5,515 |
| p-value (median) | +0.227*** (0.058) | +0.489*** (0.037) |
−0.241*** (0.066) | −0.286*** (0.046) |
−2.903*** (0.751) | −24.231*** (0.635) |
5,515 |
| p-value (max) | +0.210*** (0.068) | +0.519*** (0.038) |
−0.238*** (0.058) | −0.293*** (0.048) |
−2.700*** (0.826) | −24.686*** (0.650) |
5,515 |
| meanRankScore | +0.194*** (0.051) | +0.548*** (0.039) |
−0.261*** (0.063) | −0.279*** (0.044) |
−2.888*** (0.671) | −25.100*** (0.700) |
5,515 |
| odds ratio (median) | +0.473*** (0.106) | +0.508*** (0.041) |
−0.331*** (0.065) | −0.238*** (0.045) |
−4.808*** (1.200) | −23.638*** (0.592) |
5,515 |
| geneNtrait (gene-level) | +0.250*** (0.026) | +0.480*** (0.025) |
−0.055** (0.022) | −0.068** (0.031) |
−3.441*** (0.372) | −22.479*** (0.356) |
5,515 |
| Disease-class FE · total publications · clustered SE | Yes | ||||||
| # TIGA-matched traits | Yes | ||||||
| # GWAS-hit opportunities | No | ||||||
Table 3. Outcomes on the value tier — paper controls + # GWAS-hit opportunities
| Value definition | (1) Post2000_TIGA_H | (2) share_gene_after | (3) Delay_To_TIGA_H | N | |||
|---|---|---|---|---|---|---|---|
| Medium | High | Medium | High | Medium | High | ||
| n_study | +0.286*** (0.043) | +0.649*** (0.048) |
−0.227*** (0.047) | −0.203*** (0.034) |
−3.748*** (0.596) | −25.364*** (0.747) |
5,515 |
| p-value (median) | +0.382*** (0.058) | +0.594*** (0.038) |
−0.206*** (0.059) | −0.226*** (0.032) |
−4.541*** (0.732) | −25.143*** (0.731) |
5,515 |
| p-value (max) | +0.338*** (0.065) | +0.609*** (0.039) |
−0.205*** (0.051) | −0.228*** (0.034) |
−3.961*** (0.749) | −25.216*** (0.765) |
5,515 |
| meanRankScore | +0.310*** (0.052) | +0.594*** (0.044) |
−0.228*** (0.055) | −0.209*** (0.033) |
−3.986*** (0.640) | −25.061*** (0.804) |
5,515 |
| odds ratio (median) | +0.594*** (0.096) | +0.614*** (0.036) |
−0.303*** (0.054) | −0.200*** (0.039) |
−5.743*** (1.055) | −24.312*** (0.589) |
5,515 |
| geneNtrait (gene-level) | +0.263*** (0.026) | +0.512*** (0.023) |
−0.058*** (0.022) | −0.070** (0.031) |
−3.618*** (0.371) | −22.861*** (0.338) |
5,515 |
| Disease-class FE · total publications · clustered SE | Yes | ||||||
| # TIGA-matched traits | No | ||||||
| # GWAS-hit opportunities | Yes | ||||||
Notes. OLS; standard errors clustered by disease class in parentheses.
*** p<0.01, ** p<0.05, * p<0.1. Coefficients on
Medium and High diseases relative to Low; all six full-sample value definitions shown. Outcomes, in the
paper's column order: (1) Post2000_TIGA_H = disease has ≥1 H_TIGA gene first discovered
after 2000; (2) share_gene_after = distinct genes explored per post-2000 publication
(the value-independent gene-share / herding measure — negative = herding); (3)
Delay_To_TIGA_H = years from 1980 to the first H_TIGA discovery (censored at 39). Every estimate
keeps its sign and significance across all three specifications.